Fiche société
Orion Corporation, Orion Pharma
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications3liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ODM-208The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer. | Cancer | Phase 1/2 | À vérifier | United States, Finland, France, United Kingdom | À vérifier |
| ODM-208The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer. | Cancer | Phase 1/2 | À vérifier | United States, Finland, France, United Kingdom | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| ODM-208 | Cancer | Phase 1/2 | NCT03436485 | CYPIDES — Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| ODM-208 | Statistics of Rare Events. | NEJM evidence | ||
| ODM-208 | Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer. | NEJM evidence | ||
| ODM-208 | Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology. | Current opinion in oncology |